JP2018515107A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515107A5
JP2018515107A5 JP2017559449A JP2017559449A JP2018515107A5 JP 2018515107 A5 JP2018515107 A5 JP 2018515107A5 JP 2017559449 A JP2017559449 A JP 2017559449A JP 2017559449 A JP2017559449 A JP 2017559449A JP 2018515107 A5 JP2018515107 A5 JP 2018515107A5
Authority
JP
Japan
Prior art keywords
cells
host
strains
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017559449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515107A (ja
JP7163028B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/060919 external-priority patent/WO2016180982A1/en
Publication of JP2018515107A publication Critical patent/JP2018515107A/ja
Priority to JP2021034586A priority Critical patent/JP7465833B2/ja
Publication of JP2018515107A5 publication Critical patent/JP2018515107A5/ja
Application granted granted Critical
Publication of JP7163028B2 publication Critical patent/JP7163028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017559449A 2015-05-13 2016-05-13 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド Active JP7163028B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021034586A JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160794P 2015-05-13 2015-05-13
US62/160,794 2015-05-13
PCT/EP2016/060919 WO2016180982A1 (en) 2015-05-13 2016-05-13 T cell recruiting polypeptides based on cd3 reactivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021034586A Division JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Publications (3)

Publication Number Publication Date
JP2018515107A JP2018515107A (ja) 2018-06-14
JP2018515107A5 true JP2018515107A5 (OSRAM) 2021-04-30
JP7163028B2 JP7163028B2 (ja) 2022-10-31

Family

ID=55971009

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017559449A Active JP7163028B2 (ja) 2015-05-13 2016-05-13 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2021034586A Active JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2023068151A Active JP7763804B2 (ja) 2015-05-13 2023-04-18 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2025151363A Pending JP2025186357A (ja) 2015-05-13 2025-09-11 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021034586A Active JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2023068151A Active JP7763804B2 (ja) 2015-05-13 2023-04-18 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2025151363A Pending JP2025186357A (ja) 2015-05-13 2025-09-11 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Country Status (17)

Country Link
US (3) US11046767B2 (OSRAM)
EP (2) EP4345112A3 (OSRAM)
JP (4) JP7163028B2 (OSRAM)
CN (4) CN107847559B (OSRAM)
AU (1) AU2016260909B2 (OSRAM)
CA (2) CA2985700C (OSRAM)
DK (1) DK3294319T3 (OSRAM)
ES (1) ES2984656T3 (OSRAM)
FI (1) FI3294319T3 (OSRAM)
HR (1) HRP20240971T1 (OSRAM)
HU (1) HUE067423T2 (OSRAM)
LT (1) LT3294319T (OSRAM)
PL (1) PL3294319T3 (OSRAM)
PT (1) PT3294319T (OSRAM)
RS (1) RS65904B1 (OSRAM)
SI (1) SI3294319T1 (OSRAM)
WO (1) WO2016180982A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046767B2 (en) 2015-05-13 2021-06-29 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
IL277863B2 (en) 2018-04-11 2026-02-01 Inhibrx Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
AU2019283639A1 (en) * 2018-06-04 2021-01-07 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
CN113195544A (zh) * 2018-06-07 2021-07-30 库利南肿瘤股份有限公司 多特异性结合蛋白及其使用方法
US20210269525A1 (en) * 2018-06-29 2021-09-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-CD3e ANTIBODIES AND USES THEREOF
CA3105891A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020052542A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN113518647A (zh) 2018-10-11 2021-10-19 印希比股份有限公司 5t4单域抗体及其治疗性组合物
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN116333141B (zh) 2019-01-15 2025-10-03 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
EP4073122A4 (en) 2019-12-11 2024-03-27 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
CN113527496B (zh) * 2020-04-16 2022-03-04 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
CN111548390B (zh) * 2020-06-17 2022-09-06 清华大学深圳国际研究生院 一种cd133拮抗多肽及其衍生物与应用
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
US11795224B2 (en) * 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
WO2023079524A2 (en) * 2021-11-08 2023-05-11 Life Technologies As Polymer-interaction molecule conjugates and methods of use
WO2023141856A1 (zh) * 2022-01-27 2023-08-03 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2025251924A1 (zh) * 2024-06-07 2025-12-11 广东菲鹏制药股份有限公司 特异性结合cd3/tcr复合物的纳米抗体或其抗原结合片段及其应用
WO2026021698A1 (en) 2024-07-23 2026-01-29 BioNTech SE Nucleic acid particle
WO2026078159A1 (en) 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same
EP4729542A1 (en) 2024-10-16 2026-04-22 Universitätsklinikum Hamburg-Eppendorf Antigen-binding polypeptides against cd229

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
ES2155854T3 (es) 1993-06-09 2001-06-01 Unilever Nv Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
CN1316910A (zh) * 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003014960A2 (en) 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7958021B2 (en) 2002-09-10 2011-06-07 Igt Method and device for collecting and reporting data
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
CN102481348A (zh) * 2009-08-31 2012-05-30 Ibc药品公司 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2660895T3 (es) 2010-10-29 2018-03-26 Ablynx N.V. Método para la producción de dominios variables individuales de inmunoglobulina
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
US20140154253A1 (en) * 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
WO2014028560A2 (en) * 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP2887960A2 (en) * 2012-08-21 2015-07-01 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2769989A1 (en) * 2013-02-21 2014-08-27 Universitätsklinikum Freiburg Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
PT3049439T (pt) * 2013-09-26 2020-03-31 Ablynx Nv Nanocorpos biespecíficos
KR102093343B1 (ko) 2013-10-23 2020-03-25 삼성전자주식회사 이미지 센서 및 이미지 센서를 구동하는 방법
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US11046767B2 (en) 2015-05-13 2021-06-29 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity

Similar Documents

Publication Publication Date Title
CN112955547B (zh) 通过使用转录因子来增加蛋白质表达的手段和方法
KR20160059994A (ko) 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법
KR20170087521A (ko) 진균 게놈 변형 시스템 및 사용 방법
JP7852942B2 (ja) 活性ｄｎａトランスポゾンシステム及びその使用方法
Athmaram et al. Influence of copy number on the expression levels of pandemic influenza hemagglutinin recombinant protein in methylotrophic yeast Pichia pastoris
KR20180117147A (ko) 진핵생물을 위한 발현 시스템
RU2018126740A (ru) Пестицидные гены и способы использования
RU2019110131A (ru) Пестицидные гены и способы использования
KR20230157387A (ko) Cas 효소를 이용한 다중 편집
WO2018110471A1 (ja) 転写調節融合ポリペプチド
US20080286833A1 (en) Expression vector, a transformant carrying the same and a method for producing heterologous protein
JP2024528145A (ja) タンパク質合成および分泌のための方法および組成物
US11214809B2 (en) Vector containing centromere DNA sequence and use thereof
JPWO2012124567A1 (ja) Ｖｐｓ遺伝子が破壊されている酵母を用いる異種タンパク質の製造方法
JP2000136199A (ja) シゾサッカロミセス・ポンベで使用可能なシグナルペプチド、分泌型発現ベクター、およびそれらを用いたタンパク質生産方法
JP6944697B2 (ja) 糸状菌におけるゲノム編集を用いる多段階による多重変異株の製造方法
JP4531570B2 (ja) 封入体結合タンパク質をコードする遺伝子（ｉｂｐＡおよび／またはｉｂｐＢ）を欠失あるいは増幅させて目的タンパク質を製造する方法
US20160168198A1 (en) Signal sequence for protein expression in pichia pastoris
JP2001046078A (ja) タンパク質の高発現システム
CA2413612A1 (fr) Vecteurs d'expression comprenant un fragment modifie de l'operon tryptophane
US10266834B2 (en) Recombinant RNA particles and methods of producing proteins
JP6698993B2 (ja) ピキア酵母を用いた遺伝子組換えによるアスパルティックプロテアーゼの製造方法
FR2947840A1 (fr) Sequence promotrice pour l'expression de proteines recombinantes chez lactococcus lactis
TW202016130A (zh) ＰａＣａｓ９核酸酶
US20200172948A1 (en) Recombinant polypeptide enriched algal chloroplasts, methods for producing the same and uses thereof